DHL Group has unveiled a major €2 billion investment plan over the next five years. The investment aims to strengthen its logistics services for the life sciences and healthcare sector. This move supports the Group’s “Strategy 2030” and reflects its goal to help healthcare companies grow, innovate, and serve patients more efficiently across the globe.
The investment will enhance DHL’s infrastructure, cold chain capacity, and digital systems. It aims to create faster, more resilient, and patient-focused logistics solutions. Half of the funding will support developments in the Americas, with 25% each allocated to the Asia Pacific and EMEA regions.
DHL plans to upgrade every logistics touchpoint—from storage and fulfillment to global shipping and last-mile delivery. The company will set up new GDP-certified Pharma Hubs for multi-temperature shipping and expand its temperature-controlled vehicle fleet. It will also improve packaging solutions to support safe and sustainable deliveries.
With growing demand in clinical trials, biopharma, and advanced therapies like cell and gene treatments, DHL is investing in specialized cooling infrastructure to handle ultra-low temperature requirements. The Group will also roll out advanced IT systems to provide real-time visibility and ensure regulatory compliance and product integrity.
Under the new sector brand DHL Health Logistics, the company will unify its expertise in life sciences and healthcare. This will offer clients a seamless end-to-end service, simplifying the management of complex global supply chains. The new structure is tailored for pharmaceutical, biopharma, and medical customers needing agile and integrated logistics.
“Our investment reflects our customers’ mission: to deliver life-saving products to those in need,” said Oscar de Bok, CEO of DHL Supply Chain. “We’re building smart, integrated logistics solutions that are as reliable as the medicines our clients produce. Our goal is to ensure every patient gets the right treatment at the right time.”
In 2024, DHL Group generated over €5 billion in revenue from life sciences and healthcare. It expects to double that figure by 2030. The company currently operates nearly 600 healthcare logistics sites in almost 130 countries, covering over 2.5 million square meters of temperature-controlled warehouse space.
Also Read: DHL Group Acquires CRYOPDP to Boost Health Logistics Division.
To support this expansion, DHL has also acquired CRYOPDP, a specialty courier focused on clinical trials, biopharma, and advanced therapies. This acquisition strengthens DHL’s Pharma Specialized Network and expands its reach in critical healthcare logistics segments.
Through this bold investment, DHL is deepening its commitment to healthcare logistics and advancing its mission to support global patient care.
DHL Group has acquired 100% of CRYOPDP from Cryoport, Inc., a major provider of life sciences supply chain solutions. This move strengthens DHL’s “Health Logistics” division and expands its reach in the growing life sciences and healthcare sector.
CRYOPDP is a specialty courier company focused on clinical trials, biopharma, and cell and gene therapies. It operates in 15 countries and handles more than 600,000 shipments annually. Its services reach over 135 countries, providing essential white-glove logistics for critical healthcare needs.
The acquisition supports DHL’s strategy to grow its Life Sciences and Healthcare business, which already generated over EUR 5 billion in revenue in 2024. By integrating CRYOPDP, DHL enhances its Pharma Specialized Network with expert courier services and global air logistics support from DHL Express and DHL Global Forwarding.
Along with the acquisition, DHL Group and Cryoport announced a strategic partnership. The collaboration will combine DHL’s global logistics network with Cryoport’s niche expertise in temperature-controlled and time-sensitive shipments. It will also strengthen DHL’s ties with all Cryoport business units.
Oscar de Bok, CEO of DHL Supply Chain, called the acquisition a key step in expanding DHL’s pharma logistics. “We aim to meet the evolving needs of clinical trials, biopharma, and cell & gene therapies while expanding our footprint in traditional healthcare logistics,” he said.
Cryoport CEO Jerrell Shelton welcomed the partnership. He said the alliance opens new opportunities in key growth markets like Asia Pacific and EMEA. “Together, we will meet critical supply chain needs with enhanced solutions and wider global access,” he noted.
Also Read: DHL’s MEA Push to Boost Industrial Logistics.
This move supports DHL Group’s Strategy 2030, which prioritizes integrated, temperature-controlled solutions and end-to-end pharma logistics. The addition of CRYOPDP will help DHL reduce costs, improve service, and strengthen its leadership in advanced pharma logistics.
For Cryoport, the partnership with DHL will enable it to better execute its business in EMEA and APAC with a stronger focus on its core business in these regions, creating even greater opportunities to offer highly targeted, top-tier services in answering market demand for its services and products.
DHL Group, the world’s leading logistics company, has signed a Memorandum of Understanding (MoU) with the e-commerce marketplace Temu. The agreement aims to deepen their cooperation and further expand their successful partnership. The agreement aims to enhance collaboration to better support local small and medium-sized enterprises (SMEs) in established markets. It also seeks to extend this support to growth markets, such as Eastern Europe and the Middle East. Both parties are committed to fostering compliant trade and sustainable practices.
DHL Group will support Temu through its logistics expertise. This includes multimodal transportation solutions to provide more efficient and sustainable supply chain services. With its dense network and global presence, DHL Group is the ideal partner. It is well positioned to support Temu’s growth in both established and new markets.
“Through our various DHL divisions, we are already providing a wide range of logistics services and solutions, including air freight and last-mile delivery. We are excited to elevate our partnership with Temu to the next level. By combining our logistics capabilities with Temu’s innovative platform, we can create more efficient, compliant and convenient solutions that benefit both consumers and local businesses in the markets we serve,” states Katja Busch, CCO and Head of DHL Customer Solutions & Innovation.
Also Read: Emirates Launches Courier Service, Treating Packages Like Guests
As part of the Memorandum of Understanding, DHL Group will utilize its logistics expertise to support Temu’s operations in Europe. This includes its local-to-local model, which enables local merchandise partners to sell on its platform and supports local fulfillment. Temu expects up to 80% of its total sales in Europe to come from this local-to-local model. Additionally, the e-commerce platform will enable European-based sellers to reach global markets in the future. This allows, in particular, SMEs to scale and expand their businesses. DHL will also assist Temu in growing its presence in e-commerce markets, including the Europe, Middle East, and Africa (EMEA) regions.
“This letter of intent marks a significant step in our partnership with DHL Group. Its extensive network and logistics capabilities will help support our mission to increase consumer access to affordable products and help increase growth opportunities for sellers,” states Qin Sun, co-founder of Temu.
Technology has made the world smaller and faster.Real time communication with people from all over the world at different time zones through phones and gadgets
